Markowetz's research combines
machine learning and
artificial intelligence with experimental techniques ranging from
single cell sequencing to tissue imaging to understand the mechanisms behind chromosomal instability; how to target cancer weaknesses with therapies; how to overcome resistance to treatment; and how to improve the early detection of cancer. His team have developed a compendium of 17 copy number signatures characterising different types of chromosomal instability. These chromosomal instability signatures were able to predict how tumours might respond to drugs, as well as helping in the identification of future drug targets. This research has led to the formation of Tailor Bio, a genomics company which aims to build a new pan-cancer precision medicine platform. Markowetz's research has created artificial intelligence approaches to analyse data from the Cytosponge, a minimally invasive device to detect a precursor of oesophageal cancer. This work automates labour-intensive tasks and refines pathology biomarkers to identify the patients at the highest risk of developing cancer. == Awards and honours ==